| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $116.00 $230.00 | 12 | |
Gossypol, a polyphenolic compound, demonstrates intriguing molecular behavior through its ability to form strong π-π stacking interactions and hydrogen bonds, which enhance its binding affinity to various targets. Its unique structural features, including multiple hydroxyl groups, facilitate diverse intermolecular interactions, influencing reaction kinetics. The compound's hydrophobic regions contribute to its solubility profile, affecting its distribution in biological systems and modulating specific pathways. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
While not exclusively targeting CDK12 and CDK13, Dinaciclib is a potent CDK inhibitor that affects multiple CDKs, including CDK12 and CDKIt has been investigated for its anti-tumor effects. | ||||||
Aurora Kinase/Cdk Inhibitor | 443797-96-4 | sc-203829 | 5 mg | $440.00 | ||
While primarily a CDK9 inhibitor, JNJ-7706621 also affects CDK12 and CDK13 to some extent. It has been investigated in the context of cancer therapy. | ||||||
RGB-286638 | 784210-88-4 | sc-507523 | 250 mg | $285.00 | ||
RGB-286638 is an inhibitor that targets CDK12 and has shown potential in disrupting transcriptional processes in cancer cells. | ||||||
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
THZ1 is a covalent inhibitor of multiple CDKs, including CDK12. | ||||||